Skip to content

HCV Vaccine Trial

Clinical Trial | Hepatitis C Virus (HCV)

The Hepatitis C Virus (HCV) infects 58 million people worldwide and over 250,000 Canadians. The virus disproportionately affects marginalized populations. It is a bloodborne virus that affects the liver and is most commonly spread through unsafe injection practices, sexual practices that lead to blood exposures, and unsafe health care (i.e., transfusion of contaminated blood and blood products). If left untreated, these infections progress to liver failure and potentially liver cancer or death. Current treatments for HCV include expensive drug combinations that can cure HCV in most but do not prevent reinfection if there is another exposure. At this time, there are no vaccines available to prevent HCV and the diseases that it causes.

null

Participation Requirements

  • Sex:

    Any

  • Eligible Ages:

    18 to 45

Participation Criteria

Inclusion Criteria:
--Non-pregnant individuals, aged 18-45 years
--Currently a non-smoker and in general good health
--Intention to reside within the Edmonton area for a 13 month period
--Agree not to participate in any other clinical trial during the trial
--Agree not to donate blood for the duration of the trial
Exclusion Criteria:
--HCV positive (including those previously exposed, treated and cured)
--Any current or suspected serious chronic medical condition(s) including but not limited to bleeding disorders, impaired immune system function, inherited genetic anomaly, and current or previous history of cancer
--Pregnant or breastfeeding (all women of child bearing potential will have a negative pregnancy test resulted prior to each study product administered)
--Past significant reaction following any previous vaccination

Study Location

University of Alberta
University of Alberta
Edmonton, Alberta
Canada

Contact Study Team

Primary Contact

Kelly Kim

[email protected]
587-598-2336
Study Sponsored By
University of Alberta
Participants Required
More Information
Study ID: Pro00147152